Personalized medicine is the way forward in tackling hard-to-treat indications. Here are some of the challenges in R&D of such therapies in biotech.
By exploring use of autologous therapies, the chance of adverse responses from immunogenicity is reduced, making the treatment more targeted and effective (as doses can be higher).
Similarly, there is also a need for Biotech and Pharmaceutical policy changes to reflect these new types of drug, to evaluate their safety and help get potentially life-saving therapies to clinical trials.
Here, Genetic Insider’s Infographic highlights some of these points. Read more here.
Feature Image Credit: Antibodies binding – © Animaxx3d (BigStock ID106797554)
Let's Continue The Conversation
Feel free to send us comments about this article to firstname.lastname@example.org and/or comment on that article on social media.